100,000
Immunocompromised Americans remain without options to protect themselves from COVID, hindering their “return to normal.” We need to CLOSE THE COVID GAP, and offer Americans more treatment and preventative options for COVID. A one-size-fits-all approach is not working now and will not work going forward.
70%
Of Americans agree we must have a diverse strategy that utilizes all the prevention and treatment tools for all Americans, including those who are immunocompromised, to truly live with COVID.
50%
Of Americans agree that immunocompromised patients needing treatments such as mAbs to help protect them from COVID is a strong reason to support more approvals.
Many immunocompromised patients are unable to receive the COVID vaccine or take oral antivirals, leaving them susceptible to COVID. Monoclonal antibodies (mAbs) are a critical medical breakthrough that show incredible promise for both prevention and treatment of COVID for these patients.
mAbs are molecules developed in a laboratory that are designed to mimic or enhance the body’s natural immune system response against an invader, such as a virus or an infection.
Unfortunately, today there are no mAbs available, making it impossible for immunocompromised patients to have their return to normal. The Biden Administration and the Food and Drug Administration must prioritize the approval of these critical treatments.
info@theamericanconsumer.orgCenter for Citizen Research
4350 Fairfax Drive, #725 Arlington, VA 22203
